Mitomycin C linked to DNA minor groove binding agents: Synthesis, reductive activation, DNA binding and cross-linking properties and in vitro antitumor activity

Bioorganic and Medicinal Chemistry

Volumn 7, Issue 12, 1999, Pages 2713-2726

  Paz, Manuel M ^a   Das, Arunangshu ^a   Tomasz, Maria ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Antitumor activity; COMPARE; DNA; Mitomycin C; Mitomycin lexitropsin conjugates

Indexed keywords

AMIDE; DISTAMYCIN A; DRUG METABOLITE; MITOMYCIN C; MITOMYCIN C DERIVATIVE; N METHYLPYRROLE CARBOXAMIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CATTLE; CONTROLLED STUDY; DNA ADDUCT; DNA ALKYLATION; DNA BINDING; DNA CROSS LINKING; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; PH; REDUCTION; STRUCTURE ACTIVITY RELATION; THYMUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BASE SEQUENCE; BIOTRANSFORMATION; CATTLE; CELL-FREE SYSTEM; CROSS-LINKING REAGENTS; DNA; DNA ADDUCTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MITOMYCINS; OXIDATION-REDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0033389727     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(99)00223-0     Document Type: Article

References (44)

1. For a recent review, see Tomasz, M.; Palom, Y. Pharmacol. Ther. 1997, 76, 73.
2. Rockwell S., Kennedy K.A., Sartorelli A.C. Int. J. Radiat. Onc. Biol. Phys. 8:1982;753.
3. For a review, see Brown, M. J.; Garcia, A. J. Cancer Res. 1998, 58, 1408.
4. Siim B.G., Menke D.R., Dorie M.J., Brown M.J. Cancer Res. 57:1997;2922.
5. Haffty B.G., Son Y.H., Moini M., Papac R., Fischer D., Rockwell S., Sartorelli A.C., Fischer J.J. Radiat. Oncol. Invest. 1:1994;297.
6. Haffty B.G., Son Y.H., Sasaki C.T., Papac R., Fischer D., Rockwell S., Sartorelli A.C., Fischer J.J. Int. J. Radiat. Oncol. 27:1993;241.
7. Schiltz P., Kohn H. J. Am. Chem. Soc. 115:1993;10510.
8. Suresh Kumar G., Lipman R., Cummings J., Tomasz M. Biochemistry. 36:1997;14128.
9. Siegel D., Beall H., Senekowitsch C., Kasai M., Arai H., Gibson N.W., Ross D. Biochemistry. 31:1992;7879.
10. Chirrey L., Cummings J., Halbert G.W., Smyth J.F. Cancer Chemother. Pharmacol. 35:1995;318.
11. Palom Y., Belcourt M.F., Suresh Kumar G., Arai H., Kasai M., Sartorelli A.C., Rockwell S., Tomasz M. Oncol. Res. 10:1998;509.
12. Suresh Kumar G., He Q.Y., Behr-Ventura D., Tomasz M. Biochemistry. 34:1995;2662.
13. Peterson D.M., Fischer J., Beall H.D., Ross D. Cancer Lett. 90:1995;133.
14. Kennedy K., Sligar S.G., Polomski L., Sartorelli A.C. Biochem. Pharmacol. 11:1982;2011.
15. Keyes S.R., Fracasso P.M., Heimbrook D.C., Rockwell S., Sligar S.G., Sartorelli A.C. Cancer Res. 44:1984;5638.
16. Hodnick W.F., Sartorelli A.C. Cancer Res. 53:1993;4907.
17. Montzouris, J. A.; Hurley, L. H. In Bioorganic Chemistry: Nucleic Acids, Hecht, S. M., Ed.; Oxford University Press; New York, 1996; p 288.
18. Zimmer C., Wahnert U. Prog. Biophys. Mol. Biol. 47:1986;31.
19. Sigurdsson S.Th., Hopkins P.B. Tetrahedron. 50:1994;12065.
20. Lee M., Roldan M.C., Haskell M.K., McAdam S.R., Hartley J.A. J. Med. Chem. 9:1994;513.
21. For a comprehensive review, see Bailly, C.; Chaires, J. B. Bioconjugate Chem. 1998, 9, 513.
22. Broggini M., Erba E., Ponti M., Ballinardi D., Geroni C., Sprearico F., D'Incalci M. Cancer Res. 51:1991;199.
23. Broggini M., Coley H.M., Mongelli N., Pesenti E., Wyatt M.D., Hartley J.A., D'Incalci M. Nucleic Acids Res. 23:1995;81.
24. Boyd, M. R. In Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval: Teicher, B., Ed.; Humana Press Inc.; Totowa, NJ, 1996; pp 23-42.
25. Franck, R. W.; Tomasz, M. In Chemistry of Antitumour Agents; Wilman, D. E. V., Ed.; Chapman and Hall, New York, 1990; pp 379-394.
26. Iyengar B.S., Lyn H.-Y., Cheng L., Remers W.A. J. Med. Chem. 24:1981;975.
27. Nishiwaki E., Tanaka S., Lee H., Shibuya M. Heterocycles. 27:1988;1945.
28. Jenkins, T. C. In Methods in Molecular Biology, Vol. 90: Drug-DNA Interaction Protocols; Fox, K. R., Ed.; Humana Press, Totowa, NJ, 1997; pp 195-240.
29. Brooks N., Hartley J.A., Simpson J.E. Jr., Wright S.R., Woo S., Centioni S., Fontaine M.D., McIntyre T.E., Lee M. Bioorg. Med. Chem. 5:1997;1497.
30. Gargiulo D., Musser S.M., Yang L., Fukuyama T., Tomasz M. J. Am. Chem. Soc. 117:1995;9388.
31. Hartley J.A., Berardini M.D., Souhami R.L. Anal. Biochem. 193:1991;131.
32. Tomasz M., Lipman R. J. Am. Chem. Soc. 101:1979;6063.
33. Pan S., Andrews P.A., Bachur N.R. J. Biol. Chem. 259:1984;959.
34. Arcamone F.M., Animati F., Barbieri B., Configliacci E., D'Alessio R., Geroni C., Giuliani F.C., Lazzari E., Menozzi M., Mongelli N., Penco S., Veroni M.A. J. Med. Chem. 32:1989;774.
35. Paull K.D., Shoemaker R.H., Hodes L., Monks A., Scudiero D.A., Rubinstein L.et al. J. Natl. Cancer Inst. 81:1989;1088.
36. These tests were conducted by Dr. M. F. Belcourt; Yale University School of Medicine, New Haven, CT.
37. Wyatt M.D., Garbiras B.J., Haskell M.K., Lee M., Souhami R.L., Hartley J.A. Anti-cancer Drug Design. 9:1994;511.
38. Lee M., Rhodes A.L., Wyatt M.D., Forrow S., Hartley J.A. Anti-cancer Drug Design. 8:1993;173.
39. Wyatt M.D., Lee M., Garbiras B.J., Souhami R.L., Hartley J.A. Biochemistry. 34:1995;13034.
40. Pan S., Gonzalez H. Mol. Pharmacol. 37:1990;966.
41. Hoey B.M., Butler J., Swallow A.J. Biochemistry. 27:1988;2608.
42. Fagan P.A., Spielmann H.P., Sigurdsson S.Th., Rink S.M., Hopkins P.B., Wemmer D.E. Nucleic Acids Res. 24:1996;1566.
43. Kanaoka Y., Ikeuchi Y., Kawamoto T., Bessho K., Akimoto N., Mikata Y., Nishida M., Yano S., Sasaki T., Yoneda F. Bioorg. Med. Chem. 6:1998;301.
44. Lee M., Rhodes A.L., Wyatt M.D., D'Incalci M., Forrow S., Hartley J.A. J. Med. Chem. 36:1998;863.